Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
NeoImmuneTech
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
University of Wisconsin, Madison
Institut Cancerologie de l'Ouest
University of Alabama at Birmingham
Hoffmann-La Roche
I-Mab Biopharma US Limited
Seagen Inc.
Memorial Sloan Kettering Cancer Center
Providence Health & Services
Merck Sharp & Dohme LLC
Hoffmann-La Roche
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Takeda
Incyte Corporation
Mayo Clinic
Thomas Jefferson University
National Cancer Institute (NCI)
Fundacion Oncosur
BeiGene
Stanford University
BeiGene
Vanderbilt-Ingram Cancer Center
Georgetown University
Merck Sharp & Dohme LLC
Yale University
Sellas Life Sciences Group
University of Arkansas
Mundipharma Research Limited
The Methodist Hospital Research Institute
US Oncology Research
Hutchmed
M.D. Anderson Cancer Center
HiberCell, Inc.
Amgen
Eli Lilly and Company
Hoffmann-La Roche
Hoffmann-La Roche
City of Hope Medical Center
G1 Therapeutics, Inc.
City of Hope Medical Center
City of Hope Medical Center
M.D. Anderson Cancer Center